Okeiro, a French company specializing in precision medicine for transplantation and advanced chronic diseases, has announced a €10 million funding round to support its growth in France and internationally. The round was led by Alven, Forepont Capital Partners, and Red River West.
Revolutionizing Clinical Decision-Making with AI
At the heart of Okeiro’s mission is a cutting-edge clinical decision support platform that uses artificial intelligence to anticipate organ failure, including kidneys, lungs, heart, and liver. With kidney diseases alone affecting approximately 850 million people globally—making them a leading cause of death and accounting for 70% of all organ transplants—there is a clear and urgent need for innovative healthcare solutions. Over 250,000 patients worldwide are currently awaiting life-saving transplants.
The centerpiece of Okeiro’s platform is its proprietary algorithm, iBox. This predictive model has been clinically validated, registered as a medical device, and recognized as a surrogate biomarker by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Developed in collaboration with strategic research partners at AP-HP and INSERM, France’s leading medical research institute, iBox allows clinicians to detect post-transplant complications early, significantly improving patient monitoring and treatment protocols. It also streamlines clinical trial processes.
Already implemented in leading French transplant centers, Okeiro’s platform benefits thousands of patients and is reimbursed under France’s public health insurance system as part of a medical remote monitoring program—underscoring its clinical and organizational value.
Funding to Fuel Growth in Europe and the U.S.
The new funding will allow Okeiro to strengthen its footprint in French hospitals and expand rapidly into key European markets such as the United Kingdom, Germany, and Spain. Additionally, the company is preparing for entry into the U.S. healthcare market later this year.
Part of the capital will be allocated to enhancing the platform’s AI capabilities, improving diagnostic accuracy, refining treatment recommendations, and speeding up clinical research for chronic disease and transplant patients.
“We are deeply grateful to our investors for supporting us in this next chapter of growth,” said Pierrick Arnal, CEO and co-founder of Okeiro. “With our scientifically rigorous foundation and AI models validated through extensive clinical trials, Okeiro is committed to transforming transplant medicine on a global scale. Our goal is to redefine patient care by leveraging technology to elevate clinical outcomes, enhance the patient experience, and accelerate the development of next-generation therapies.”
Investors See Game-Changing Potential
Dr. Ismail Kola, Partner at Forepont Capital Partners, expressed strong confidence in the company’s trajectory: “We’re excited to invest in Okeiro, whose breakthrough algorithm can predict kidney graft failure years before symptoms appear. Regulatory agencies now accept this technology as a clinical trial surrogate endpoint, which drastically reduces drug development timelines and costs. Beyond transplantation, the potential applications for chronic kidney disease are incredibly promising. We’re highly impressed by the scientific excellence led by Prof. Loupy and Pierrick’s leadership in addressing critical unmet medical needs.”
François Meteyer, Partner at Alven, added, “At Alven, we are passionate about supporting clinical software companies with proprietary medical IP and a U.S. market focus. Okeiro fits this vision perfectly. Much like our previous investment in Cardiologs within cardiology, we’re excited to back Okeiro in scaling its precision medicine solution and building a leading commercial presence in chronic disease management.”
Looking ahead, the urgency is growing. By 2040, chronic kidney disease (CKD) is expected to become the fifth leading cause of death worldwide. In the U.S., CKD is even more prevalent than in other regions, affecting 15% of the population—compared to 10% globally.
With its innovative technology and ambitious roadmap, Okeiro is positioning itself at the forefront of a healthcare transformation that could benefit millions of patients worldwide.
